Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1043]

Josep Tabernero to head ESMO

Josep Tabernero to head ESMO

Stress hormones could undermine breast cancer therapy

Stress hormones could undermine breast cancer therapy

ASCO 2015: First effective adjuvant chemotherapy for high-risk, localised prostate cancer

ASCO 2015: First effective adjuvant chemotherapy for high-risk, localised prostate cancer

ASCO 2015: Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

ASCO 2015: Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

ASCO 2015: Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

ASCO 2015: Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

New drug combination shows promise for breaking breast cancer resistance

New drug combination shows promise for breaking breast cancer resistance

AACR 2015: Dual mTOR inhibitor-fulvestrant combo feasible, with clinical benefit for advanced breast cancer patients

AACR 2015: Dual mTOR inhibitor-fulvestrant combo feasible, with clinical benefit for advanced breast cancer...

AACR 2015: Investigational ER degrader safe, with early signs of antitumour activity against advanced ER-positive breast cancer

AACR 2015: Investigational ER degrader safe, with early signs of antitumour activity against advanced ER-positive...

Two trials show efficacy for enzalutamide in prostate cancer

Two trials show efficacy for enzalutamide in prostate cancer

ASCO GU: Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy

ASCO GU: Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy

More from ecancer